Edition:
United Kingdom

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

49.62USD
22 Jun 2018
Change (% chg)

$3.87 (+8.46%)
Prev Close
$45.75
Open
$45.82
Day's High
$49.81
Day's Low
$45.63
Volume
1,033,237
Avg. Vol
441,557
52-wk High
$153.98
52-wk Low
$38.45

Latest Key Developments (Source: Significant Developments)

Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer
Monday, 26 Mar 2018 

March 26 (Reuters) - Tesaro Inc ::DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER.TESARO INC - ‍EFFICACY OF NIRAPARIB IN COMBINATION WITH AN ANTI-PD-1 MAB SURPASSES HISTORICAL EFFICACY BENCHMARKS FOR PD-1 OR PARP MONOTHERAPIES​.TESARO INC - COMBINATION OF NIRAPARIB WITH PEMBROLIZUMAB WAS WELL TOLERATED WITH AN INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA OF 9%.TESARO-POTENTIAL APPROACH TO REDUCE INCIDENCE OF GRADE 3 OR 4 THROMBOCYTOPENIA IDENTIFIED BASED ON RETROSPECTIVE ANALYSIS OF DATA FROM PHASE 3 NOVA TRIAL.TESARO - IN ADDITION TO THROMBOCYTOPENIA, OTHER MOST COMMONLY OBSERVED GRADE ≥3 ADVERSE EVENTS N STUDY INCLUDED ANEMIA AND NEUTROPENIA.  Full Article

Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION.TESARO INC - CHANGES TO LABELING INCLUDE MODIFICATIONS TO CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, AND ADVERSE REACTIONS SECTIONS.TESARO - ANAPHYLAXIS, ANAPHYLACTIC SHOCK HAVE BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING, SOME REQUIRING HOSPITALIZATION.TESARO - OTHER "SERIOUS" HYPERSENSITIVITY REACTIONS HAVE ALSO BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING.TESARO - MOST REACTIONS HAVE OCCURRED DURING OR SOON AFTER INFUSION OF VARUBI INJECTABLE EMULSION AND WITHIN FIRST FEW MINUTES OF ADMINISTRATION.  Full Article

Tesaro secures $500 million non-dilutive term loan financing
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Tesaro Inc :Tesaro secures $500 million non-dilutive term loan financing.Loans will mature in December 2024​.Loan facility provides Tesaro with up to $500 million of borrowing capacity available in two tranches​.Plan to use proceeds to strengthen PARP inhibitor franchise in ovarian cancer, expand development of Zejula in other tumor types​.  Full Article

Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Tesaro Inc :Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer.Tesaro Inc - ‍approval supported by "robust" data from a randomized phase 3 trial​.Tesaro Inc - ‍Tesaro plans to launch Zejula in Germany and UK this December, with launches in additional European countries to follow beginning in 2018​.  Full Article

Tesaro reports Q3 loss per share $0.47
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Tesaro Inc ::Tesaro announces third-quarter 2017 operating results.Q3 loss per share $0.47.Q3 revenue $142.8 million versus I/B/E/S view $132.8 million.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Tesaro Inc - ‍positive CHMP opinion issued for zejula in e.u. & commercial launch anticipated to begin by year-end​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

Tesaro and Zai Lab announce collaboration, development and license agreement
Thursday, 29 Sep 2016 

Tesaro Inc: Tesaro and zai lab announce collaboration, development and license agreement . Tesaro has granted to Zai Lab an exclusive license for development of niraparib specifically for china market . Tesaro retains right to co-market in China and receives option to license up to two novel immuno-oncology programs outside China . Companies will establish a joint steering committee to review and oversee all development and commercialization plans . Tesaro will be eligible to receive milestone payments contingent upon Zai Lab achieving certain specified development and commercial goals . Initiated a rolling submission of a new drug application (NDA) for niraparib to FDA, and intends to complete this submission during Q4 . Should co elect not to participate in commercialization of niraparib in china,co willreceive royalty payments on annual net sales from Zai Lab . Tesaro has option to license two novel, discovery-stage immuno-oncology programs from Zai Lab . Additional financial details were not disclosed .Marketing authorization application (MAA) for niraparib is planned for submission to european medicines agency (EMA) in Q4.  Full Article

Tesaro Q2 loss per share $1.28
Thursday, 4 Aug 2016 

Tesaro Inc :Q2 loss per share $1.28.  Full Article

Tesaro posts Q2 shr loss $1.28
Thursday, 4 Aug 2016 

Tesaro Announces Second : Quarter 2016 operating results . Q2 earnings per share view $-1.71 -- Thomson Reuters I/B/E/S .Q2 loss per share $1.28.  Full Article

Engot and Tesaro present positive data from ovarian cancer drug
Friday, 8 Jul 2016 

Tesaro: Engot and Tesaro partnership generates positive data from engot-ov16/nova phase 3 trial . Engot and Tesaro partnership generates positive data from engot-ov16/nova phase 3 trial . Says Engot-OV16/NOVA's NDA and MAA submissions are planned for Q4 2016 .Engot-OV16/NOVA trial successfully achieved its primary endpoint of PFS in germline BRCA mutant cohort.  Full Article

BRIEF-Tesaro Announces Collaboration To Evaluate Zejula In Combination With Anti-PD-L1 Cancer Immunotherapy, MEK Inhibitor In Platinum-Sensitive Ovarian Cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE ZEJULA® IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY AND MEK INHIBITOR IN PLATINUM-SENSITIVE OVARIAN CANCER